Trial
NCT05189756
Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
—
Condition
Postoperative Nausea and Vomiting
Intervention
Aprepitant 80 mg
Why stopped
Low recruiting rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-27